Page 74 - Read Online

Page 16 of 17 Chi et al. J Cancer Metastasis Treat 2020;6:43 I http://dx.doi.org/10.20517/2394-4722.2020.90

2016;34:e15747.
54. O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal
adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 2019;5:1431-8.
55. Ng J, Dai T. Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med 2016;4:118.
56. Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci 2014;15:927-43.
57. Tsuchikawa T, Hirano S, Tanaka E, et al. Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in
pancreatic cancer. Cancer Sci 2013;104:531-5.
58. Homma Y, Taniguchi K, Murakami T, et al. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline
resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 2014;21:670-6.
59. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in
cancer. Nature 2015;520:373-7.
60. Seifert L, Werba G, Tiwari S, et al. Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in
mice. Gastroenterology 2016;150:1659-72.e5.
61. Katz MHG, Varadhachary GR, Bauer TW, et al. Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant
chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic
cancer. J Clin Oncol 2017;35:4125.
62. Lutz ER, Wu AA, Bigelow E, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune
regulation. Cancer Immunol Res 2014;2:616-31.
63. Wu AA, Jaffee E, Lee V. Current status of immunotherapies for treating pancreatic cancer. Curr Oncol Rep 2019;21:60.
64. Ward JP, Gubin MM, Schreiber RD. The role of neoantigens in naturally occurring and therapeutically induced immune responses to
cancer. Adv Immunol 2016;130:25-74.
65. Johnson BA, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res
2017;23:1656-69.
66. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the
administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
67. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015;21:687-92.
68. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine
for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
69. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor
vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011;253:328-35.
70. Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-
CSF gene in previously treated pancreatic cancer. J Immunother Hagerstown Md 1997 2013;36:382-9.
71. Inc LP. NewLink genetics announces results from phase 3 IMPRESS trial of Algenpantucel-L for patients with resected pancreatic cancer.
GlobeNewswire News Room. 2016. Available from: http://www.globenewswire.com/news-release/2016/05/09/837878/0/en/NewLink-
Genetics-Announces-Results-from-Phase-3-IMPRESS-Trial-of-Algenpantucel-L-for-Patients-with-Resected-Pancreatic-Cancer.html.
[Last accessed on 30 Oct 2020]
72. Lauer P, Chow MYN, Loessner MJ, Portnoy DA, Calendar R. Construction, characterization, and use of two Listeria monocytogenes site-
specific phage integration vectors. J Bacteriol 2002;184:4177-86.
73. Brockstedt DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl
Acad Sci U S A 2004;101:13832-7.
74. Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing
mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol Off 2015;33:1325-33.
75. Le DT, Picozzi VJ, Ko AH, et al. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared
with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study). Clin Cancer Res
2019;25:5493-502.
76. A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000
plus gem versus gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of
the R1 subgroup. Available from: https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.e14501. [Last accessed on 30 Oct 2020]
77. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Lessons from randomized phase III studies with active
cancer immunotherapies - outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007;25:B97-109.
78. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217-21.
79. Yamaue H, Tsunoda T, Tani M, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer:
PEGASUS-PC study. Cancer Sci 2015;106:883-90.
80. Asahara S, Takeda K, Yamao K, Maguchi H, Yamaue H. Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from
KIF20A for patients with advanced pancreatic cancer. J Transl Med 2013;11:291.
81. Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor
as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-50.
82. VXM01, an oral T-cell vaccine targeting the tumor vasculature: results from a randomized, controlled, first-in-man study in pancreatic
cancer patients. Available from: https://meetinglibrary.asco.org/record/84680/abstract. [Last accessed on 30 Oct 2020]
83. Kondo H, Hazama S, Kawaoka T, et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and